Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA)

Advances in Experimental Medicine and Biology

Volumn 685, Issue , 2010, Pages 64-74

  Katsuno, Masahisa ^a   Banno, Haruhiko ^b   Suzuki, Keisuke ^b   Adachi, Hiroaki ^b   Tanaka, Fumiaki ^b   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; ANDROGEN RECEPTOR; GELDANAMYCIN; HEAT SHOCK PROTEIN; LEUPRORELIN; TEPRENONE; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CAG REPEAT; CLINICAL FEATURE; DRUG INHIBITION; ENZYME REGULATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KENNEDY DISEASE; MITOCHONDRION; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MOTONEURON; MOTONEURON NUCLEUS; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN QUALITY; UBIQUITINATION; ANIMAL; ANTERIOR HORN CELL; BRAIN STEM; FEMALE; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT; SPINAL MUSCULAR ATROPHY; TRINUCLEOTIDE REPEAT;

ANIMALIA;

ANIMALS; ANTERIOR HORN CELLS; BRAIN STEM; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; RECEPTORS, ANDROGEN; SEX CHARACTERISTICS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 77955883056     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6448-9_6     Document Type: Article

References (62)

1. Fischbeck KH. Kennedy disease. J Inherit Metab Dis 1997; 20:152-158. (Pubitemid 27273478)
2. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18:671-680.
3. Katsuno M, Adachi H, Waza M et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp Neurol 2006; 200:8-18. (Pubitemid 44080751)
4. Pachatz C, Terracciano C, Desiato MT et al. Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clin Neurophysiol 2007; 118:262-268. (Pubitemid 46038810)
5. Atsuta N, Watanabe H, Ito M et al. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. Brain 2006; 129:1446-1455. (Pubitemid 43999377)
6. Takeuchi Y, Katsuno M, Banno H et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008; 38:964-971.
7. Sperfeld AD, Hanemann CO, Ludolph AC et al. Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 2005; 64:753-754. (Pubitemid 40261918)
8. Suzuki K, Katsuno M, Banno H et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008; 131:229-239.
9. Inoue K, Hemmi S, Miyaishi M et al. Muscular fatigue and decremental response to repetitive nerve stimulation in X-linked spinobulbar muscular atrophy. Eur J Neurol 2009; 16:76-80.
10. Dejager S, Bry-Gauillard H, Bruckert E et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocr Metab 2002; 87:3893-3901. (Pubitemid 34879545)
11. Sobue G, Doyu M, Kachi T et al. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J Neurol Sci 1993; 117:74-78. (Pubitemid 23274652)
12. La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77-79. (Pubitemid 21896702)
13. Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. Hum Mol Genet 1997; 6:2005-2010. (Pubitemid 27477941)
14. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: Mechanism and principles. Nat Rev Genet 2005; 6:743-755. (Pubitemid 41400832)
15. Tanaka F, Doyu M, Ito Y et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 1996; 5:1253-1257. (Pubitemid 26335842)
16. Doyu M, Sobue G, Mukai E et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992; 32:707-710.
17. Palazzolo I, Gliozzi A, Rusmini P et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 2008; 108:245-253. (Pubitemid 351187919)
18. Sobue G, Hashizume Y, Mukai E et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989; 112:209-232. (Pubitemid 19056483)
19. Li M, Miwa S, Kobayashi Y et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998; 44:249-254. (Pubitemid 28374114)
20. Arrasate M, Mitra S, Schweitzer ES et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431:805-810. (Pubitemid 39434070)
21. Nagai Y, Inui T, Popiel HA et al. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 2007; 14:332-340. (Pubitemid 46608340)
22. Adachi H, Katsuno M, Minamiyama M et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005; 128:659-670. (Pubitemid 40380200)
23. Banno H, Adachi H, Katsuno M et al. Mutant androgen receptor accumulation in SBMA scrotal skin: A pathogenic marker. Ann Neurol 2006; 59:520-526. (Pubitemid 43358073)
24. Poletti A. The polyglutamine tract of androgen receptor: From functions to dysfunctions in motor neurons. Front. Neuroendocrinol 2004; 25:1-26. (Pubitemid 38744538)
25. Adachi H, Kume A, Li M et al. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum Mol Genet 2001; 10:1039-1048. (Pubitemid 32447781)
26. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: Mechanisms and hypothesis. J Mol Neurosci 2004; 23:69-96.
27. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005; 6:11-22. (Pubitemid 40052135)
28. Li M, Chevalier-Larsen ES, Merry DE et al. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem 2007; 282:3157-3164. (Pubitemid 47084317)
29. Katsuno M, Adachi H, Kume A et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35:843-854.
30. Yu Z, Dadgar N, Albertelli M et al. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol 2006; 168:195-204. (Pubitemid 43062573)
31. Montie HL, Cho MS, Holder L et al. Cytoplasmic Retention of Polyglutamine-Expanded Androgen Receptor Ameliorates Disease via Autophagy in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Hum Mol Genet 2009 (Epub ahead of print).
32. Takeyama K, Ito S, Yamamoto A et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002; 35:855-864.
33. Chevalier-Larsen ES, O'Brien CJ, Wang H et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004; 24:4778-4786. (Pubitemid 38668202)
34. Katsuno M, Adachi H, Minamiyama M et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J Neurosci 2006; 26:12106-12117. (Pubitemid 44808377)
35. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ et al. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002; 59:770-772.
36. Kinirons P, Rouleau GA. Administration of testosterone results in reversible deterioration in Kennedy's disease. J Neurol Neurosurg Psychiatry 2008; 79:106-107.
37. Lin X, Antalffy B, Kang D et al. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 2000; 3:157-163. (Pubitemid 30126331)
38. Luthi-Carter R, Strand A, Peters NL et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000; 9:1259-1271. (Pubitemid 30312475)
39. Hay DG, Sathasivam K, Tobaben S et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 2004; 13:1389-1405. (Pubitemid 38961645)
40. Katsuno M, Sang C, Adachi H et al. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA 2005; 102:16801-16806. (Pubitemid 41688857)
41. Nucifora FC Jr, Sasaki M, Peters MF et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291:2423-2428. (Pubitemid 32231807)
42. Steffan JS, Bodai L, Pallos J et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413:739-743. (Pubitemid 33009952)
43. Minamiyama M, Katsuno M, Adachi H et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004; 13:1183-1192. (Pubitemid 38787000)
44. Sopher BL, Thomas PS Jr, LaFevre-Bernt MA et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004; 41:687-699. (Pubitemid 38326832)
45. Suzuki E, Zhao Y, Ito S et al. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity. Proc Natl Acad Sci USA 2009; 106:3818-3822.
46. Puls I, Jonnakuty C, LaMonte BH et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33:455-456. (Pubitemid 36390002)
47. Hafezparast M, Klocke R, Ruhrberg C et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003; 300:808-812. (Pubitemid 36532118)
48. Morfini G, Pigino G, Szebenyi G et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 2006; 9:907-916. (Pubitemid 43980505)
49. Young JE, Garden GA, Martinez RA et al. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 2009; 29:1987-1997.
50. Ranganathan S, Harmison GG, Meyertholen K et al. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 2009; 18:27-42.
51. Custer SK, Garden GA, Gill N et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 2006; 9:1302-1311. (Pubitemid 44454272)
52. Monks DA, Johansen JA, Mo K et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci USA 2007; 104:18259-18264. (Pubitemid 350210854)
53. Katsuno M, Adachi H, Doyu M et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9:768-773. (Pubitemid 36749228)
54. Banno H, Katsuno M, Suzuki K et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009; 65:140-150.
55. Yang Z, Chang YJ, Yu IC et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007; 13:348-353. (Pubitemid 46376683)
56. Palazzolo I, Burnett BG, Young JE et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet 2007; 16:1593-1603. (Pubitemid 47050673)
57. Tokui K, Adachi H, Waza M et al. 17-DMAG ameliorates polyglutamine- mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 2009; 18:898-910.
58. Waza M, Adachi H, Katsuno M et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005; 11:1088-1095. (Pubitemid 41486831)
59. Adachi H, Katsuno M, Minamiyama M et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 2003; 23:2203-2211. (Pubitemid 36368908)
60. Bailey CK, Andriola IF, Kampinga HH et al. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 2002; 11:515-523. (Pubitemid 34257488)
61. Adachi H, Waza M, Tokui K et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 2007; 27:5115-5126. (Pubitemid 46741791)
62. Ying M, Xu R, Wu X et al. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 2006; 281:12580-12586. (Pubitemid 43855346)